Solvonis Therapeutics Expands R&D Pipeline with Awakn Acquisition

Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an announcement.

Solvonis Therapeutics plc has completed the acquisition of Awakn Life Sciences Corp., significantly expanding its research and development pipeline. This acquisition enhances Solvonis’ position in developing treatments for addiction and mental health disorders, with a particular focus on Alcohol Use Disorder and Post-Traumatic Stress Disorder. The acquisition includes the investigational therapy SVNS-001, currently in a Phase 3 clinical trial for severe Alcohol Use Disorder in the UK. This strategic move is expected to accelerate Solvonis’ R&D efforts and strengthen its market position in the biopharmaceutical industry.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London, focusing on developing innovative treatments for addiction and mental health disorders. The company is listed on the London Stock Exchange and is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet needs, such as Alcohol Use Disorder and Post-Traumatic Stress Disorder.

Average Trading Volume: 10,789,241

Technical Sentiment Signal: Sell

Current Market Cap: £3.04M

For an in-depth examination of SVNS stock, go to TipRanks’ Stock Analysis page.